Like other startups, WuXi had a humble start. Founded on its strength in chemistry and expanded gradually to other services needed for international drug makers to conduct clinical trials in China, WuXi came up to compete ...
Also, a medicine hoped to treat solid tumors developed by BeiGene, a Beijing-based pharma, is being tested clinically. It is a potential "first-in-class" candidate that uses a new and unique mechanism for treating disease. It came after RemeGen, a Yantai-based pharma, obtained the marketing...
In the last 12 months, many US-listed Chinese firms have listed or plan to list shares on the Hong Kong Exchange. Companies already listed include Alibaba (HK:9988), JD.com (HK:9618), Beigene (HK:6160) and Netease (HK:9999).
In recent years, except for the launch of NEJM in the head-to-head Phase III clinical trial of VV116, only BTK inhibitor Zebtinib of Beigene has "defeated" ibutinib on NEJM due to the dual superior effect of ORR and PFS in the head-to-head phase III. However, the number of domes...
As gene therapy progresses, the safety implications of these agents from a surgical perspective should be evaluated, as currently there is a sparsity of literature in this regard. Finally, a more detailed understanding of the safety profiles of immunotherapeutic agents in this context would be ...
Ou reports receiving honoraria from AstraZeneca, Caris Life Science, Daiichi Sankyo, Jassen/JNJ, Merck, Pfizer, Roche/Genentech, Takeda/ARIAD, BeiGene, and DAVA Oncology LLP; is a scientific advisory board member of Elevation Oncology; and has previous ownership interest in Turning Point ...
BeiGene extends partnership with Medidata to use Patient Cloud ePRO The Awards, which are free to enter, aim to recognise the progression in the applications of recycled plastics, which EPRO says presents an opportunity for the industry to further demonstrate commitment to the environment and savin...
BeiGene is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Its product portfolio includes the anti-PD-1 antibody tislelizumab.We entered into a clinical collaboration...
Additionally, the safety results from the combined experience in four ongoing monotherapy trials demonstrate that zanubrutinib was generally well-tolerated," commented Jane Huang, M.D., Chief Medical Officer, Hematology, at BeiGene. BeiGene provides development update, presents clinical data on zanu...
As gene therapy progresses, the safety implications of these agents from a surgical perspective should be evaluated, as currently there is a sparsity of literature in this regard. Finally, a more detailed understanding of the safety profiles of immunotherapeutic agents in this context would be ...